Omeprazol Basi (Omeprazole)

Omeprazole, the active ingredient in Omeprazol Basi, is a proton pump inhibitor presented as a strength/form for oral use. It reduces stomach acid production and is used to treat acid‑related gastrointestinal conditions in adults and children. GNH USA supplies Omeprazol Basi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Omeprazol Basi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Omeprazole is a proton pump inhibitor that acts on the gastric acid secretion pathway. It is indicated for several acid‑related disorders: - Gastro‑esophageal reflux disease (GERD): provides relief of heartburn and promotes healing of erosive esophagitis. - Peptic ulcer disease: supports ulcer healing and reduces recurrence risk. - Zollinger‑Ellison syndrome: controls excessive gastric acid secretion associated with gastrin‑producing tumors. - Helicobacter pylori eradication regimens: used as part of combination therapy to improve eradication rates. - NSAID‑induced ulcer prevention: lowers the risk of ulcer formation in patients requiring chronic NSAID therapy.

Omeprazole is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhea: usually transient. - Nausea: occasional mild upset. - Abdominal pain: mild discomfort. - Flatulence: increased gas. - Constipation: occasional.

Serious or Rare Side Effects: - Severe allergic reaction: rash, itching, swelling, or difficulty breathing. - Clostridioides difficile infection: persistent watery diarrhea. - Low magnesium levels: muscle cramps, irregular heartbeat. - Bone fracture risk: especially with long‑term use. - Acute interstitial nephritis: kidney inflammation. - Hepatotoxicity: elevated liver enzymes or jaundice.

When using Omeprazol Basi, consider the following safety measures: - Assess renal function: adjust use in severe renal impairment. - Evaluate hepatic function: use with caution in moderate to severe liver disease. - Review long‑term therapy: periodic assessment of need and lowest effective dose. - Monitor for nutrient deficiencies: calcium, magnesium, and vitamin B12 may be reduced. - Avoid abrupt discontinuation: taper to prevent rebound acid hypersecretion. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Omeprazole may affect the pharmacokinetics of several co‑administered medicines.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect, may increase cardiovascular risk. - Atazanavir and other protease inhibitors: decreased absorption, loss of antiviral efficacy.

Moderate Interactions (Monitor Closely): - Warfarin: potential increase in INR, monitor coagulation parameters. - Methotrexate: increased serum levels, watch for toxicity. - Digoxin: higher plasma concentrations, assess for signs of digoxin toxicity. - Phenytoin: reduced clearance, may require dose adjustment.